NCT05781542View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

October 2, 2024

Study Completion Date

April 14, 2025

Conditions
HIV Infections
Interventions
BIOLOGICAL

sD-NP-GT8 DNA

0.4 mg or 1.6 mg

BIOLOGICAL

IL-12 DNA

0.1 mg or 0.4 mg

BIOLOGICAL

Trimer 4571

100 mcg

BIOLOGICAL

3M-052-AF

5 mcg

DRUG

Alum

500 mcg

Trial Locations (8)

4013

CAPRISA eThekwini CRS, Durban

7925

Groote Schuur HIV CRS (Site ID: 31708), Cape Town

35294

Alabama CRS (Site ID: 31788), Birmingham

94102

Bridge HIV CRS, San Francisco

San Francisco Vaccine and Prevention CRS, San Francisco

02115

Brigham and Women's Hospital Vaccine CRS [30007], Boston

Unknown

Soweto HVTN CRS, Johannesburg

Durban Adult HIV CRS, Durban

Sponsors

Collaborators (1)

Inovio Pharmaceuticals
All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

collaborator

The Wistar Institute

OTHER

collaborator

The Betty and Dale Bumpers Vaccine Research Center (VRC)

UNKNOWN

collaborator

Inovio Pharmaceuticals

INDUSTRY

collaborator

Access to Advanced Health Institute (AAHI)

OTHER

collaborator

Department of Health and Human Services

FED

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05781542 - Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV | Biotech Hunter | Biotech Hunter